Oriplantee

Oriplantee Company Limited is a biotechnology firm specializing in the development of novel botanical-derived therapeutics, with a primary focus on oncology. The company's lead investigational candidate, Orialpha (BD-C), is a botanical drug derived from the plant Uvaria grandiflora (known locally in Vietnam as Bù dẻ tía). The primary active constituent of Orialpha is Zeylenone, a polyoxygenated cyclohexene that has demonstrated potent anti-tumor activity by targeting key pathways such as NF-κB and EZH2. Oriplantee is currently advancing Orialpha through Phase I clinical trials to evaluate its safety, tolerability, and pharmacokinetics, specifically targeting breast cancer and other solid tumors.